iiinova — where your digital self keeps evolving

Scintillon Institute @scintillon.bsky.social · 25/08/2026

Dr. Irene Pedersen from the Scintillon Institute with colleagues at Columbia University Medical Center found targeting neutralization of microRNA-23b strengthens blood-brain barrier (BBB) function, accelerates repair, and reduces ischemic injury in stroke models. www.scintillon.org/news/microrn...

scintillon.org

RNA based gene therapy for stroke — The Scintillon Research Institute

010

Scintillon Institute @scintillon.bsky.social · 25/08/2026

The Scintillon Research Institute welcomed 12 talented students for the 2026 SURE Program this summer, bringing another energetic group of young scientists into our laboratories for an immersive introduction to biomedical research. www.scintillon.org/sure-program...

scintillon.org

SURE Program 2026 — The Scintillon Research Institute

000

Scintillon Institute @scintillon.bsky.social · 17/08/2026

Dr. Valentin Cracan (@scintillon.bsky.social) and Dr. Andrey Parkhitko (University of Pittsburgh) have been awarded two R21 grants from the NIH to study how redox metabolism shapes aging and cancer, and whether modulating it can delay both. www.scintillon.org/news/redoxme...

scintillon.org

Redox Metabolism Research — The Scintillon Research Institute

010

Scintillon Institute @scintillon.bsky.social · 03/12/2025

Congratulations to Associate Professor Irene Pedersen for receiving a R61/R33 grant from the NIH to study neuro-immune-vascular dynamics in preclinical neuroHIV model. www.scintillon.org/news/neuro-h...

scintillon.org

Pedersen lab awarded NIH R61/R33 grant — The Scintillon Research Institute

020

Scintillon Institute @scintillon.bsky.social · 28/11/2025

In a collaborative study led by Dr. Tal Teitz, Associate Professor at the Scintillon Research Institute, with Drs. Jian Zuo, Yunlong Huang and colleagues from Ting Therapeutics, Inc, a selective CDK2 inhibitor was evaluated as a potential otoprotectant. www.scintillon.org/oral-cdk2-in...

scintillon.org

Oral CDK2 Inhibitor is a clinically translatable drug for cisplatin-induced hearing loss — The Scintillon Research Institute

010

Scintillon Institute @scintillon.bsky.social · 12/11/2025

Pomelo Biosciences, a new incubator company at the Scintillon Research Institute working on rejuvenation and regenerative medicine. www.scintillon.org/pomelo-biosc...

scintillon.org

Spotlight Series on our Incubator companies: Pomelo Biosciences Inc — The Scintillon Research Institute

010

Scintillon Institute @scintillon.bsky.social · 05/11/2025

Congratulations to our faculty, Dr. Brian Lawson, for receiving a Healthy Longevity Catalyst Award from the National Academy of Medicine for developing microglia with chimeric antigen receptors (CAR-microglia) as treatment for multiple sclerosis. www.scintillon.org/brian-lawson...

scintillon.org

Groundbreaking CAR-Microglia approach to Treat Multiple Sclerosis — The Scintillon Research Institute

040